Comparison

MOUSE ANTI HUMAN SHIP-1 (N-TERMINAL)

Manufacturer GENWAY
Category
Type Antibody
Specific against Human
Applications WB
Amount 0.1 mg
Host Mouse
Item no. 20-783-314759
eClass 6.1 32160702
eClass 9.0 32160702
Available
Genway ID:
GWB-BCD685
Specificity:
SHIP-1 (N-TERMINAL)
Isotype:
IgG2a
Preparation:
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution:
Phosphate buffered saline pH7. 4
Preservative Stabilisers:
0. 09% Sodium Azide (NaN3)Approx. Protein Concentrations: IgG concentration 1. 0mg/ml
Immunogen:
Synthetic peptide corresponding to a sequence within the N-terminal (NT) region of human SHIP-1.
Specificity:
Specifically recognises an epitope within the N-terminal (NT) region of human SHIP-1 (SH2 domain-containing inositol phosphatase 1) an inositol 5-phosphatase and member of the inositol-1 4 5-trisphosphate 5-phosphatase family primarily expressed by haematopoietic cells which acts as a signal transduction protein and negative regulator in lymphocyte and myeloid cell growth pathways. Recommended Secondary Antibodies: Rabbit Anti Mouse IgGGoat Anti Mouse IgGHuCAL Anti Mouse IgG2aRabbit Anti Mouse IgGGoat Anti Mouse IgG (H/L)Goat Anti Mouse IgG IgA IgMGoat Anti Mouse IgG (Fc)Sheep Anti Mouse IgG (H/L)
Function:
Phosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol-3 4 5-trisphosphate (PtdIns(3 4 5)P3) to produce PtdIns(3 4)P2 thereby negatively regulating the PI3K (phosphoinositide 3-kinase) pathways. Acts as a negative regulator of B-cell antigen receptor signaling. Mediates signaling from the FC-gamma-RIIB receptor (FCGR2B) playing a central role in terminating signal transduction from activating immune/hematopoietic cell receptor systems. Acts as a negative regulator of myeloid cell proliferation/survival and chemotaxis mast cell degranulation immune cells homeostasis integrin alpha-IIb/beta-3 signaling in platelets and JNK signaling in B-cells. Regulates proliferation of osteoclast precursors macrophage programming phagocytosis and activation and is required for endotoxin tolerance. Involved in the control of cell-cell junctions CD32a signaling in neutrophils and modulation of EGF-induced phospholipase C activity. Key regulator of neutrophil migration by governing the formation of the leading edge and polarization required for chemotaxis. Modulates FCGR3/CD16-mediated cytotoxicity in NK cells. Mediates the activin/TGF-beta-induced apoptosis through its Smad-dependent expression. May also hydrolyze PtdIns(1 3 4 5)P4 and could thus affect the levels of the higher inositol polyphosphates like InsP6. Ref. 9Ref. 11Catalytic activity1-phosphatidyl-1D-myo-inositol 3 4 5-triphosphate + H2O = 1-phosphatidyl-1D-myo-inositol 3 4-diphosphate + phosphate. Ref. 1Ref. 3Enzyme regulationActivated upon translocation to the sites of synthesis of PtdIns(3 4 5)P3 in the membrane By similarity. Subunit structureInteracts with tyrosine phosphorylated forms of SHC1 DOK1 DOK3 PTPN11/SHP-2 SLAMF1/CD150. Interacts with PTPN11 in response to IL-3. Interacts with receptors EPOR MS4A2/FCER1B and FCER1G FCGR2A FCGR2B and FCGR3. Interacts with GRB2 and PLCG1. Interacts with tyrosine kinases SRC and TEC. Interacts with FCGR2A leading to regulate gene expression during the phagocytic process. Interacts with c-Met/MET By similarity. Ref. 3Ref. 2Ref. 5Ref. 7Ref. 8Subcellular locationCytoplasm. Membrane; Peripheral membrane protein.
Note:
Translocates to the plasma membrane when activated translocation is probably due to different mechanisms depending on the stimulus and cell type. Partly translocated via its SH2 domain which mediates interaction with tyrosine phosphorylated receptors such as the FC-gamma-RIIB receptor (FCGR2B) or CD16/FCGR3. Tyrosine phosphorylation may also participate to membrane localization By similarity. Ref. 8Tissue specificitySpecifically expressed in immune and hematopoietic cells. Expressed in bone marrow and blood cells. Levels vary considerably within this compartment. Present in at least 74% of immature CD34+ cells whereas within the more mature population of CD33+ cells it is present in only 10% of cells. Present in the majority of T-cells while it is present in a minority of B-cells (at protein level). Ref. 1Ref. 2Ref. 5Ref. 4
Domain:
The SH2 domain interacts with tyrosine phosphorylated forms of proteins such as SHC1 or PTPN11/SHP-2. It competes with that of GRB2 for binding to phosphorylated SHC1 to inhibit the Ras pathway. It is also required for tyrosine phosphorylation By similarity. The NPXY sequence motif found in many tyrosine-phosphorylated proteins is required for the specific binding of the PID domain By similarity. Post-translational modificationTyrosine phosphorylated by the members of the SRC family after exposure to a diverse array of extracellular stimuli such as cytokines growth factors antibodies chemokines integrin ligands and hypertonic and oxidative stress. Phosphorylated upon IgG receptor FCGR2B-binding. Ref. 5Ref. 8Ref. 10Ref. 12Sequence similaritiesBelongs to the inositol-1 4 5-trisphosphate 5-phosphatase family. Contains 1 SH2 domain. Sequence cautionThe sequence AAC50454. 1 differs from that shown. Reason: Erroneous initiation.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 0.1 mg
Available: In stock
available

Delivery expected until 5/30/2024 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close